doi: 10.1016/j.bodyim.2025.101890, 94 MartinC
For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another
To help counteract these effects and restore optimal health, Glutathione levels can be replenished through injections, promoting a return to balance and vitality in the body
This article has been viewed 536,062 times
Monitoring and Side Effect Management: Throughout the course of treatment, continuous monitoring by a medical professional is vital
This post covers why temperature control is vital for medication stability, what happens if your medication accidentally freezes, and how to store your supplies properly to protect your investment in your health
